[go: up one dir, main page]

WO1999009967A3 - Cholesterol-lowering therapy - Google Patents

Cholesterol-lowering therapy Download PDF

Info

Publication number
WO1999009967A3
WO1999009967A3 PCT/US1998/017459 US9817459W WO9909967A3 WO 1999009967 A3 WO1999009967 A3 WO 1999009967A3 US 9817459 W US9817459 W US 9817459W WO 9909967 A3 WO9909967 A3 WO 9909967A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol level
average
density lipoprotein
cholesterol
lipoprotein cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/017459
Other languages
French (fr)
Other versions
WO1999009967A2 (en
WO1999009967B1 (en
Inventor
Edwin J Whitney
Geraldine Mantell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814415.7A external-priority patent/GB9814415D0/en
Priority claimed from GBGB9815851.2A external-priority patent/GB9815851D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to CA002300165A priority Critical patent/CA2300165A1/en
Priority to AU91153/98A priority patent/AU9115398A/en
Priority to EP98943329A priority patent/EP1007019A2/en
Publication of WO1999009967A2 publication Critical patent/WO1999009967A2/en
Publication of WO1999009967A3 publication Critical patent/WO1999009967A3/en
Publication of WO1999009967B1 publication Critical patent/WO1999009967B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods are described for preventing or reducing the risk of a first occurrence of a cardiovascular event using an HMG-CoA reductase inhibitor alone or in combination with another lipid altering agent. Subjects to be treated are those having an average serum total cholesterol level, an average to mildly elevated serum low-density lipoprotein cholesterol level, and a below average serum high-density lipoprotein cholesterol level, with no history of clinically evident coronary disease.
PCT/US1998/017459 1997-08-26 1998-08-21 Cholesterol-lowering therapy Ceased WO1999009967A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002300165A CA2300165A1 (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy
AU91153/98A AU9115398A (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy
EP98943329A EP1007019A2 (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US5696697P 1997-08-26 1997-08-26
US60/056,966 1997-08-26
US7685998P 1998-03-05 1998-03-05
US60/076,859 1998-03-05
US8536098P 1998-05-13 1998-05-13
US60/085,360 1998-05-13
GBGB9814415.7A GB9814415D0 (en) 1998-07-03 1998-07-03 Cholesterol-lowering therapy
GB9814415.7 1998-07-03
GB9815851.2 1998-07-21
GBGB9815851.2A GB9815851D0 (en) 1998-07-21 1998-07-21 Cholesterol-lowering therapy

Publications (3)

Publication Number Publication Date
WO1999009967A2 WO1999009967A2 (en) 1999-03-04
WO1999009967A3 true WO1999009967A3 (en) 1999-05-20
WO1999009967B1 WO1999009967B1 (en) 1999-07-08

Family

ID=27517467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017459 Ceased WO1999009967A2 (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy

Country Status (4)

Country Link
EP (1) EP1007019A2 (en)
AU (1) AU9115398A (en)
CA (1) CA2300165A1 (en)
WO (1) WO1999009967A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR100596257B1 (en) 2001-01-26 2006-07-03 쉐링 코포레이션 Compositions comprising a sterol absorption inhibitor, and compositions and combinations comprising a peroxisomal growth factor-activated receptor activator and a sterol absorption inhibitor
SI1355644T1 (en) 2001-01-26 2006-10-31 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MXPA04002573A (en) 2001-09-21 2004-06-18 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461548A2 (en) * 1990-06-11 1991-12-18 E.R. SQUIBB & SONS, INC. Method for preventing a second heart attack employing and HMG CoA reductase inhibitor
EP0528515A2 (en) * 1991-06-04 1993-02-24 Merck & Co. Inc. HMG-CoA reductase inhibitors in the prevention of restenosis following coronary angioplasty
EP0671171A1 (en) * 1994-01-18 1995-09-13 Bristol-Myers Squibb Company Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461548A2 (en) * 1990-06-11 1991-12-18 E.R. SQUIBB & SONS, INC. Method for preventing a second heart attack employing and HMG CoA reductase inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
EP0528515A2 (en) * 1991-06-04 1993-02-24 Merck & Co. Inc. HMG-CoA reductase inhibitors in the prevention of restenosis following coronary angioplasty
EP0671171A1 (en) * 1994-01-18 1995-09-13 Bristol-Myers Squibb Company Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HARIA M. ET AL: "Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.", DRUGS, (1997) 53/2 (299-336). REFS: 267 ISSN: 0012-6667 CODEN: DRUGAY, New Zealand, XP002095845 *
KELLICK K A ET AL: "Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.", AMERICAN JOURNAL OF CARDIOLOGY, (1995 JUL 13) 76 (2) 62A-64A. JOURNAL CODE: 3DQ. ISSN: 0002-9149., United States, XP002095843 *
MARCUS A.: "Role of the HMG-CoA reductase inhibitors in the treatment of dyslipidemia An evolutionary review.", CARDIOVASCULAR REVIEWS AND REPORTS, (1996) 17/1 (10-11+15-16+21-24+26-27) ISSN: 0197-3118 CODEN: CRRPD4, United States, XP002095841 *
MEISER, B. M. ET AL: "Simvastatin decreases accelerated graft vessel disease (GVD) after heart transplantation in an animal model", TRANSPLANT. PROC. (1993), 25(2), 2077-9 CODEN: TRPPA8;ISSN: 0041-1345, XP002095842 *
MOTOMURA N. ET AL: "HMG-CoA reductase inhibitors in organ transplantation.", JOURNAL OF NEPHROLOGY, (1997) 10/2 (68-76). REFS: 127 ISSN: 1121-8428 CODEN: JLNEEL, Italy, XP002095844 *
PFEIFER M.A. ET AL: "Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) 76/9 (98C-106C). ISSN: 0002-9149 CODEN: AJCDAG, United States, XP000579209 *
PROBSTFIELD, JEFFREY L. (1) ET AL: "Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) VOL. 76, NO. 9, PP. 47C-53C. ISSN: 0002-9149., XP002095840 *
SOUTHWORTH M R ET AL: "The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.", ANNALS OF PHARMACOTHERAPY, (1997 APR) 31 (4) 489-91. REF: 32 JOURNAL CODE: BBX. ISSN: 1060-0280., United States, XP002095847 *
STEIN E. ET AL: "Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, (1997) 2/1 (7-16). REFS: 30 ISSN: 1074-2484 CODEN: JCPTFE, United States, XP002095846 *

Also Published As

Publication number Publication date
AU9115398A (en) 1999-03-16
WO1999009967A2 (en) 1999-03-04
CA2300165A1 (en) 1999-03-04
WO1999009967B1 (en) 1999-07-08
EP1007019A2 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
WO1999009967A3 (en) Cholesterol-lowering therapy
AU5074196A (en) Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
UA88265C2 (en) Use of inhibitors of the renin-angiotensin system in the prevention of diabetes
PL307463A1 (en) Pharmaceutical agent especially for inhibiting osteoporosis and lowering cholesterol level in blood serum
WO2000028981A3 (en) Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
WO1999066031A3 (en) Pharmaceutical factor vii preparation
WO2000015211A3 (en) Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders
WO1998051289A3 (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
FI951218A7 (en) Method for reducing total cholesterol and low-density lipoprotein cholesterol levels in the blood
EP0713706A3 (en) Lipoprotein (a) lowering agent, cholesterol lowering agent and medicaments comprising these agents respectively
EP0989852A4 (en) Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2003099281A3 (en) Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
WO2000069445A8 (en) Combination therapy for treating hypercholesterolemia
WO1998001100A3 (en) Method for treating homozygous familial hypercholesterolemia
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
HK1042852A1 (en) Method of enhancing insulin action
AU5544994A (en) Use of 17alpha-dihydroequilenin for lowering cholesterol
Campeau Lipid lowering and coronary bypass graft surgery
BG105471A (en) METHOD OF PREVENTING OR DELAYING THE REQUESTS OF THE REVIVALCIZATION CATHETER
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
Smith Jr Review of recent clinical trials of lipid lowering in coronary artery disease
NZ505637A (en) E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions useful in lowering serum cholesterol
PL368572A1 (en) Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
WO2002007753A3 (en) Method for treating unstable angina pectoris

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2300165

Country of ref document: CA

Ref country code: CA

Ref document number: 2300165

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998943329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 91153/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998943329

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998943329

Country of ref document: EP